What is compounded tirzepatide?
Compounded tirzepatide is a customized preparation of the tirzepatide molecule prepared by a 503A licensed compounding pharmacy or a 503B FDA-registered outsourcing facility. It is dispensed in response to a patient-specific prescription (503A) or in batches (503B). It is not FDA-approved and is not the same product as Mounjaro® (FDA-approved for type 2 diabetes) or Zepbound® (FDA-approved for chronic weight management and obstructive sleep apnea), both manufactured by Eli Lilly.
Base vs salt forms (regulatory line)
The active pharmaceutical ingredient must be tirzepatide base. The FDA has issued warning letters specifically against compounded tirzepatide preparations using salt forms (tirzepatide acetate, tirzepatide sodium), citing that these are not pharmacologically equivalent to the base molecule. A legitimate compounded tirzepatide provider should be able to produce a certificate of analysis showing the active ingredient is tirzepatide base.
The 503A vs 503B pathway
- 503A: State-licensed compounding pharmacy. Prepares patient-specific medications under USP <797> sterile-compounding standards. Not FDA-inspected for product release. Beyond-use dates are typically shorter.
- 503B: FDA-registered outsourcing facility. Operates under cGMP (the same standard as commercial drug manufacturers). Can prepare batches in advance of patient-specific prescriptions. FDA-inspected.
Read the full 503A vs 503B explainer →
Provider pricing comparison (May 2026)
| Provider | Monthly | Notes |
|---|---|---|
| NexLife (Editor's Pick) | $186/mo (12-mo plan) | Flat across 2.5–15 mg titration. MD/DO-supervised, 503A + 503B. |
| Mochi Health | $239/mo | NP-led model. |
| Hims compounded | $249–$349/mo | Tiered by dose at some points. |
| Henry Meds | $379/mo | Async NP model. |
Quality assurance documentation to ask for
- Pharmacy of record on every shipment — name and license number of the 503A or 503B that prepared the medication.
- USP <71> sterility certificate — confirmation that the batch passed sterility testing.
- USP <85> endotoxin certificate — confirmation of pyrogen safety.
- HPLC potency certificate — confirmation of correct concentration of active ingredient.
- Per-vial lot traceability — the patient should be able to trace every dose to a specific batch and CoA.
Clinical context
Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist. SURMOUNT-1 (NEJM 2022, PMID 35658024) demonstrated 20.9% mean weight loss at 15 mg / 72 weeks. SURMOUNT-OSA (NEJM 2024) demonstrated apnea-hypopnea index reduction in obesity-related OSA. The boxed warning is for thyroid C-cell tumors; contraindicated in personal/family history of MTC or MEN-2.